



Contact: **Alix Aassila**, Chief Marketing Officer | CosmoFrance
(305) 538-0110 | marketing@cosmofrance.net | www.cosmofrance.net

Clinical study confirms effectiveness of autologous **EZGEL®** PRF for nasolabial folds treatment

MIAMI, FLORIDA – May 19, 2025 – A new peer-reviewed clinical study demonstrates that **EZGEL®** PRF, an autologous bio-regenerative treatment, significantly **reduces moderate-to-severe nasolabial folds**, commonly known as "smile lines," with **progressive improvement over 24 weeks**. These facial creases, which run from the sides of the nose to the corners of the mouth, are a primary cosmetic concern for many individuals seeking aesthetic treatments. The findings offer aesthetic practitioners a clinically validated, natural alternative to synthetic dermal fillers.



*Patient showing significant reduction in nasolabial fold severity from baseline (left) to 24 weeks post-treatment (right) following the **EZGEL** PRF protocol.*

The study, titled "Effectiveness of an Autologous Filler in Patients with Moderate-to-Severe Nasolabial Folds," was conducted by researchers Angela Cong, LaRyel Waldon, Aurelio Aquila, Sharon Stewart PA-C, Amit Kochhar MD, FACS, and Kian Karimi MD, FACS. It evaluated 15 subjects with grade 3-4 nasolabial folds (**indicating moderate to severe wrinkle depth on the standardized Wrinkle Severity Rating Scale**) over a 24-week period using advanced 3D imaging technologies including Vectra® 3D Analysis Module and QuantifiCare® LifeViz Infinity. The peer-reviewed study was published in Facial Plastic Surgery & Aesthetic Medicine, Volume 00, Number 00, 2025, and additional information about the research methodology and findings is available upon request.

"These study results confirm what we've observed clinically – **EZGEL®** provides both immediate volumization and long-term bio-regenerative effects for **natural-looking facial rejuvenation**," said Kian Karimi MD, FACS. "The **92.3% patient satisfaction rate** demonstrates **EZGEL®'s** effectiveness as a natural alternative to synthetic fillers in the evolving aesthetic market."




Study lead investigators Kian Karimi MD, FACS (left) and Amit Kochhar, MD, FACS (right) at Rejuva Medical Aesthetics where the clinical trial was conducted.

KEY FINDINGS:

- **Patient satisfaction** reached **92.3%** at week 20, with 46% reporting their results as **"very much improved"**
- Maximum volume increase of **1.31 cc** measured at **week 16**, with statistical significance ($p = 0.032$), confirming the treatment's measurable impact
- Wrinkle severity scores decreased from an average of **3.3 (moderate-severe)** at **baseline to 0.75 (mild)** by study conclusion
- Some subjects experienced **midface lifting effects** beyond the treated nasolabial fold areas
- **Excellent safety profile** with only one reported adverse event that resolved without complications

Average Wrinkle Severity Rating Scale



Progressive improvement in Wrinkle Severity Rating Scale (WSRS) scores throughout the **24-week study**, with most significant results achieved after the third treatment.



The **EZGEL**® system includes the **EZMINISPIN**® Centrifuge and **EZHEAT**® thermal processing unit, enabling practitioners to create 100% autologous biofiller from the patient's own blood.

EZGEL® harnesses Platelet-Rich Fibrin (PRF), a 100% autologous biostimulant containing vital growth factors including PDGF, VEGF, TGF- β , EGF, and IGF-1. The proprietary **EZGEL**® system transforms standard PRF into an advanced biofiller through specialized technology, including the **EZMINISPIN**® Centrifuge and **EZHEAT**® thermal processing system.

The treatment protocol involved strategic injections at baseline, **week 4**, and **week 16**, with comprehensive follow-up evaluations. The multi-plane injection capability allows practitioners to target subcutaneous, subdermal, and periosteal layers for comprehensive facial rejuvenation.

For more information about **EZGEL**® PRF, to request study details, or to arrange an interview with the researchers, please contact marketing@cosmoFrance.net.

"This clinical study conclusively demonstrates that **EZGEL**® PRF is both **safe and effective** as a natural alternative for treating nasolabial folds and **achieving natural facial rejuvenation**," said Dr. Luc Dewandre, President of CosmoFrance. "With its excellent safety profile and progressive improvements over time, **EZGEL**® represents a significant advancement for practitioners seeking **science-backed, regenerative aesthetic solutions for patients** who prefer **natural alternatives to synthetic fillers**."

ABOUT COSMOFRANCE

Founded in 1997, CosmoFrance has established itself as a pioneer in the medical aesthetics industry, specializing in manufacturing, importing, and distributing **high-quality medical devices to US aesthetic practitioners**. The company has a proven track record of introducing innovative non-invasive procedures that set practitioners apart, including the revolutionary **DermaSculpt® microcannula** in 2010 and the **EZPRF®** system in 2017. Building on its expertise in regenerative aesthetics, CosmoFrance continues to advance natural, autologous treatments through its latest **EZGEL®** technology, providing practitioners with cutting-edge solutions that **harness the body's own healing capabilities**. With a dedicated team focused on exceptional customer service, CosmoFrance remains committed to identifying and developing the next trends in aesthetic medicine.



Note: This press release includes forward-looking statements and technical descriptions of medical procedures. **EZGEL®** PRF should be administered only by qualified medical professionals in accordance with proper protocols and regulations.

Media Kit Available: High-resolution images, complete study results, researcher bios are available upon request. Contact marketing@cosmofrance.net for access.

Social Media: Follow CosmoFrance for updates on **EZGEL®** and regenerative aesthetics:

 [@cosmofrance](https://twitter.com/cosmofrance)

 [CosmoFrance](https://www.linkedin.com/company/cosmo-france)

